Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
Allergy · 2023-02 · 78 (2) · 389-401
DOI: 10.1111/all.15603 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 07.12.2022. Verfasst von Allen Kaplan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Char…. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria, Chronic Urticaria. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near‐daily basis, over >6 weeks; many patients experience flare‐ups over several years and, consequently, reduced quality of life. Differences between the inflammatory profiles of the skin of CSU patients (wheals and nonlesional sites) and healthy controls indicate that key drivers such as mast cells, eosinophils, and basophils interact, release vasoactive mediators, and prime the skin, leaving patients predisposed to symptoms. Many cytokines and chemokines involved in these inflammatory networks and their corresponding intracellular signaling cascades have been identified. These insights informed the development of therapies such as omalizumab, dupilumab, and Bruton's tyrosine kinase (BTK) inhibitors, marking a renewed focus on pathogenesis in CSU clinical research. Despite progress, current therapies provide symptomatic control but do not appear to redress the inflammatory balance in the skin permanently. A deeper understanding of CSU pathogenesis will permit a more targeted approach to developing novel treatments with curative intent. Here, we review what is known about the pathogenesis of CSU and consider how this can be used to identify rational targets to improve patient care further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Dermatology, Hospital del Mar, Institut Mar D'Investigacions Mediques, Universitat Autònoma and Universitat Pompeu Fabra, Barcelona, Spain.
- Department of Dermatology, Hiroshima Citizens Hospital and Department of Dermatology, Hiroshima University, Hiroshima, Japan.
- Department of Dermatology, University of Southern California, Los Angeles, California, USA.
- Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Allen Kaplan, Ana M Giménez-Arnau, Marcus Maurer
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Kaplan, A., Lebwohl, M., Giménez-Arnau, A. M., Hide, M., Armstrong, A. W., & Maurer, M. (2023). Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy, 78(2), 389-401. https://doi.org/10.1111/all.15603
Vancouver
Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389-401. doi:10.1111/all.15603
BibTeX
@article{Kaplan2023,
author = {Kaplan, Allen and Lebwohl, Mark and Giménez-Arnau, Ana M and Hide, Michihiro and Armstrong, April W and Maurer, Marcus},
title = {Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances},
journal = {Allergy},
year = {2023},
volume = {78},
number = {2},
pages = {389--401},
doi = {10.1111/all.15603}
}
EUVIMED